{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"96.9","upperLimit":"100","value":"98.7"},{"groupId":"OG001","lowerLimit":"95","upperLimit":"99.4","value":"97.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"163"},{"groupId":"OG001","value":"220"}],"units":"Participants"}],"description":"Disease-free survival (DFS) is evaluated in patients treated with trastuzumab emtansine, which is defined per protocol: from the time of randomization until the to the occurrence of the first of the following events:\n\n* Local/regional recurrence: a recurrent or new invasive ipsilateral breast cancer, invasive breast cancer in the axilla, regional lymph nodes, chest wall, or skin of the ipsilateral breast.\n* Contralateral invasive breast cancer,\n* Distant recurrence: metastatic disease that has either been biopsy confirmed or clinically diagnosed as recurrent invasive breast cancer. A single new lesion on a bone scan without evidence of lytic disease on x-ray and without symptoms does not in and of itself constitute distant recurrence, but multiple new bone lesions, or increased isotope uptake associated with new bone symptoms are more likely due to metastases. Bone metastases must be documented with x-rays and clinical description.\n* Death from any cause","dispersionType":"95% Confidence Interval","groups":[{"description":"T-DM1 3.6mg/kg every three weeks by IV for 17 doses for a total of 51 weeks","id":"OG000","title":"Trastuzumab Emtansine (T-DM1) With Tumor Size < 1 cm"},{"description":"T-DM1 3.6mg/kg every three weeks by IV for 17 doses for a total of 51 weeks","id":"OG001","title":"Trastuzumab Emtansine (T-DM1) With Tumor Size >= 1 cm"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"3 years","title":"3-year T-DM1 iDFS Percentage by Tumor Size and Hormone Receptor (HR) Status","type":"SECONDARY","unitOfMeasure":"percentage of participants"}